Kalaris VP granted 10,000 stock options at $4.10

Kalaris Therapeutics, Inc. (KLRS) reported that officer Amy O'Leary Vandekop, VP, Corporate Controller, received a grant of stock options for 10,000 shares of common stock.

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. (KLRS) reported that officer Amy O'Leary Vandekop, VP, Corporate Controller, received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $4.10 per share, expire on August 26, 2036, and vest over four years, with 25% vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Vandekop Amy O'Leary

Role VP, Corporate Controller

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

Key Figures

Stock options granted: 10,000 shares Exercise price: $4.10 per share Shares underlying option: 10,000 shares +3 more

6 metrics

Stock options granted 10,000 shares Stock Option (Right to Buy) granted on August 27, 2026

Exercise price $4.10 per share Conversion or exercise price of stock option grant

Shares underlying option 10,000 shares Common Stock underlying the derivative security

Expiration date August 26, 2036 Expiration of stock option grant

Vesting cliff portion 25% of 10,000 shares Vests on August 1, 2027, subject to continuous service

Post-transaction derivative holdings 10,000 options Total stock options held following the reported grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying the option are scheduled to vest over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"vesting in equal monthly installments thereafter, subject to continuous service"

FAQ

What insider transaction did KLRS report for Amy O'Leary Vandekop?

Kalaris Therapeutics, Inc. reported a grant of stock options for 10,000 shares of common stock to officer Amy O'Leary Vandekop, VP, Corporate Controller, on August 27, 2026 as a compensation-related award.

What is the exercise price of the new KLRS stock options granted to Amy O'Leary Vandekop?

The stock options granted to Amy O'Leary Vandekop have an exercise price of $4.10 per share, allowing her to purchase Kalaris Therapeutics, Inc. common stock at that price if the options vest and are exercised before expiration.

How many KLRS shares underlie the stock options granted on August 27, 2026?

The stock option grant to Amy O'Leary Vandekop covers 10,000 shares of Kalaris Therapeutics, Inc. common stock, all reported as directly owned following the transaction.

When do Amy O'Leary Vandekop’s KLRS options start vesting and what is the schedule?

The options begin vesting with 25% of the shares on August 1, 2027. The remaining 75% of the 10,000 underlying shares vest in equal monthly installments over the following years, subject to continuous service.

When do the newly granted KLRS stock options to Amy O'Leary Vandekop expire?

The stock options granted to Amy O'Leary Vandekop are scheduled to expire on August 26, 2036, if not exercised earlier and subject to the vesting and service conditions described in the grant.

Is the KLRS insider transaction part of a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmatively marked for this Form 4. The reported transaction is a grant of stock options, not an open-market trade under a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:11 PM Accepted by SEC EDGAR 08/28/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vandekop Amy O'Leary

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Corporate Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.1	08/27/2026		A		10,000		(1)	08/26/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

	/s/ Amy O'Leary Vandekop	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)